Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Etoposide-Cisplatin Alternating with Vinorelbine-Cisplatin Versus Etoposide-Cisplatin Alone in Patients with Extensive Disease Combined with Small Cell Lung Cancer

  • Zhang, Jie (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Qi, Hui-Wei (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Zheng, Hui (Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Chen, Mo (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Zhu, Jun (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Xie, Hui-Kang (Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Ni, Jian (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Xu, Jian-Fang (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Zhou, Cai-Cun (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine)
  • Published : 2014.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The aim of this study was to evaluate the efficacy of alternating etoposide-cisplatin and vinorelbine-cisplatin (EP-NP) compared with an etoposide-cisplatin (EP) regimen for advanced combined small cell carcinomas. Materials and Methods: Histologically confirmed combined small cell carcinoma patients who met the inclusion criteria were randomly assigned (1:1) into either the EP-NP setting (group A) or the EP setting (group B). The primary endpoint was progression-free survival in patients who received at least one dose of treatment. Results: Eighty-two patients entered into this trial, 42 in group A and 40 in group B. The objective response rates in group A and group B were 42.9% and 32.5%, respectively (p=0.334). Survival analysis showed that median progression-free survival was 6.1 months in group A, which was significantly longer than the 4.1 months in group B (p=0.041). However, as to overall survival, no significant difference was found between the two groups (11.0 vs 10.1 months in groups A and B, respectively, p=0.545). No unexpected side effects were observed in either group. Conclusions: The EP-NP regimen for combined small cell carcinomas prolonged progressio-nfree survival compared with the EP regimen. Further clinical investigations are warranted.

Keywords

References

  1. Adelstein DJ, Tomashefski JF Jr, Snow NJ, et al (1986). Mixed small cell and non-small cell lung cancer. Chest, 89, 699-704. https://doi.org/10.1378/chest.89.5.699
  2. Babakoohi S, Fu P, Yang M, et al (2013). Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer, 14, 113-9. https://doi.org/10.1016/j.cllc.2012.07.002
  3. Bai H, Wang Z, Chen K, et al (2012). Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol, 30, 3077-83. https://doi.org/10.1200/JCO.2011.39.3744
  4. Bishop JA, Sharma R, Illei PB (2010). Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Human Pathol, 41, 20-5. https://doi.org/10.1016/j.humpath.2009.06.014
  5. Faller BA, Pandit TN (2011). Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Clin Med Insights Oncol, 5, 131-44.
  6. Fushimi H, Kikui M, Morino H, et al (1996). Histologic changes in small cell lung carcinoma after treatment. Cancer, 77, 278-83. https://doi.org/10.1002/(SICI)1097-0142(19960115)77:2<278::AID-CNCR9>3.0.CO;2-I
  7. Goldberg SB, Oxnard GR, Digumarthy S, et al (2013). Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist, 18, 1214-20. https://doi.org/10.1634/theoncologist.2013-0168
  8. Hage R, Elbers JR, Brutel de la Riviere A, et al (1998). Surgery for combined type small cell lung carcinoma. Thorax, 53, 450-3. https://doi.org/10.1136/thx.53.6.450
  9. Hanna N, Bunn PA Jr, Langer C, et al (2006). Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensivestage disease small-cell lung cancer. J Clin Oncol, 24, 2038-43. https://doi.org/10.1200/JCO.2005.04.8595
  10. Hsiao HH, Tsai HJ, Liu YC, et al (2006). A rare case of combined small-cell lung cancer with unusual soft tissue metastasis. Kaohsiung J Med Sci, 2, 352-6.
  11. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA: A Cancer J Clinicians, 60, 277-300. https://doi.org/10.3322/caac.20073
  12. Kalhor N, Zander DS, Liu J (2006). TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously papstained cytologic material. Mod Pathol, 19, 1117-23.
  13. Lara PN Jr, Natale R, Crowley J, et al (2009). Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol, 27, 2530-5. https://doi.org/10.1200/JCO.2008.20.1061
  14. Luo J, Wu FY, Li AW, et al (2012). Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study. Asian Pac J Cancer Prev, 13, 4703-6. https://doi.org/10.7314/APJCP.2012.13.9.4703
  15. Mangum MD, Greco FA, Hainsworth JD, et al (1989). Combined small-cell and non-small-cell lung cancer. J Clin Oncol, 7, 607-12.
  16. Murase T, Takino H, Shimizu S, et al (2003). Clonality analysis of different histological components in combined small cell and non-small cell carcinoma of the lung. Human Pathol, 34, 1178-84. https://doi.org/10.1053/j.humpath.2003.05.001
  17. Murray N, Turrisi AT 3rd (2006). A review of first-line treatment for small-cell lung cancer. J Thorac Oncol, 1, 270-8.
  18. Nicholson SA, Beasley MB, Brambilla E, et al (2002). Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol, 26, 1184-97. https://doi.org/10.1097/00000478-200209000-00009
  19. Schiller JH, Adak S, Cella D, et al (2001). Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 19, 2114-22.
  20. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  21. Schneider BJ (2008). Management of recurrent small cell lung cancer. J Natl Compr Canc Netw, 6, 323-31.
  22. Simon GR, Wagner H, American College of Chest Physicians (2003). Small cell lung cancer. Chest, 123, S259-71. https://doi.org/10.1378/chest.123.1_suppl.259S
  23. Socinski MA, Weissman C, Hart LL, et al (2006). Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol, 24, 4840-7. https://doi.org/10.1200/JCO.2006.07.7016
  24. Stupp R, Monnerat C, Turrisi AT 3rd, et al (2004). Small cell lung cancer: state of the art and future perspectives. Lung Cancer, 45, 105-17. https://doi.org/10.1016/j.lungcan.2003.12.006
  25. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  26. Weng CT, Chu PY, Liu MT, et al (2008). Small cell carcinoma of the head and neck: a single institution's experience and review of the literature. J Otolarynglo Head Neck Surg, 37, 788-93.
  27. Wong YN, Jack RH, Mak V, et al (2009). The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004. BMC Cancer, 9, 209. https://doi.org/10.1186/1471-2407-9-209
  28. Zheng Y, Xu N, Zhou J (2013). Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? Lancet Oncol, 14, 438. https://doi.org/10.1016/S1470-2045(13)70153-0

Cited by

  1. Relationship Between the SER Treatment Period and Prognosis of Patients with Small Cell Lung Cancer vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6415
  2. High pretreatment serum C-reactive protein level predicts a poor prognosis for combined small-cell lung cancer vol.36, pp.11, 2015, https://doi.org/10.1007/s13277-015-3611-z
  3. Medicinal Plants: A Potential Source of Compounds for Targeting Cell Division vol.9, pp.1177-3928, 2015, https://doi.org/10.4137/DTI.S24946
  4. Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent vol.6, pp.8, 2017, https://doi.org/10.1002/cam4.1131